NCT05575388

Brief Summary

The aim of the study is to assess the prevalence and pattern of isolated fungi from patients with lung cancer at the time of diagnosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2018

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2020

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

October 6, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 12, 2022

Completed
Last Updated

October 12, 2022

Status Verified

October 1, 2022

Enrollment Period

2.6 years

First QC Date

October 6, 2022

Last Update Submit

October 10, 2022

Conditions

Keywords

lung cancer, fungal colonization, fiberoptic bronchoscopy

Outcome Measures

Primary Outcomes (1)

  • number of participants with positive fungal growth

    assessed by fungal culture of BAL

    April 2018 and October 2020

Secondary Outcomes (1)

  • predictors of fungal infection in lung cancer participants

    April 2018 and October 2020

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients definitely diagnosed as central bronchogenic carcinoma

You may qualify if:

  • All patients definitely diagnosed as central bronchogenic carcinoma from positive cytopathology of specimens taken through investigation by FOB before receiving any specific treatment.

You may not qualify if:

  • the presence of neutropenia with an absolute neutrophil count \< 1,000/µL (equivalent to \< 1.0 × 109/L)
  • patients on systemic corticosteroids therapy or those on chemotherapy or radiotherapy or antifungal treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine

Al Mansurah, 35516, Egypt

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 6, 2022

First Posted

October 12, 2022

Study Start

March 1, 2018

Primary Completion

October 1, 2020

Study Completion

October 1, 2020

Last Updated

October 12, 2022

Record last verified: 2022-10

Locations